Good afternoon, and thank you for joining the ReShape Lifesciences Third Quarter 2024 Conference Call. I would like to turn the call over to Michael Miller from Rx Communications. Good afternoon, ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

REMAIN-1 weight maintenance pivotal study enrollment progressing rapidly; mid-point data analysis expected in Q2 2025 ...